New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Abstract Background Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, respectively. It was granted marketing authorization in India in 2013 for...

Full description

Bibliographic Details
Main Authors: Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil, Ashok Jaiswal
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Cardiovascular Diabetology
Subjects:
Saroglitazar
Dual PPAR agonist
Diabetic dyslipidemia
Triglyceride
Glycosylated hemoglobin
Alanine aminotransferase
Online Access:http://link.springer.com/article/10.1186/s12933-019-0884-3

Internet

http://link.springer.com/article/10.1186/s12933-019-0884-3

Similar Items